Increased serum pentraxin 3 in patients with systemic sclerosis

Journal of Rheumatology

Volumn 36, Issue 5, 2009, Pages 976-983

  Iwata, Yohei ^a   Yoshizaki, Ayumi ^a   Ogawa, Fumihide ^a   Komura, Kazuhiro ^a   Hara, Toshihide ^a   Muroi, Eiji ^a   Takenaka, Motoi ^a   Shimizu, Kazuhiro ^a   Hasegawa, Minoru ^b   Fujimoto, Manabu ^b   Takehara, Kazuhiko ^b   Sato, Shinichi ^a  

^a NAGASAKI UNIVERSITY GRADUATE SCHOOL OF BIOMEDICAL SCIENCES   (Japan)

^b KANAZAWA UNIVERSITY GRADUATE SCHOOL OF MEDICAL SCIENCE   (Japan)

Author keywords

Hyaluronan; Inflammation; Oxidative stress; Pentraxin 3; Systemic sclerosis

Indexed keywords

8 ISOPROSTANE; HYALURONIC ACID; IMMUNOGLOBULIN; PENTRAXIN 3; TOLL LIKE RECEPTOR; ACUTE PHASE PROTEIN; BIOLOGICAL MARKER; C REACTIVE PROTEIN; CARBON MONOXIDE; DIAGNOSTIC AGENT; SERUM AMYLOID P;

ADULT; ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; ENZYME LINKED IMMUNOSORBENT ASSAY; ERYTHROCYTE SEDIMENTATION RATE; FEMALE; HEART DISEASE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LUNG FIBROSIS; MAJOR CLINICAL STUDY; MALE; OXIDATIVE STRESS; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; PROTEIN SYNTHESIS; SCORING SYSTEM; SKIN ULCER; SKINFOLD THICKNESS; SYSTEMIC SCLEROSIS; BLOOD; CELL CULTURE; DIFFUSE SCLERODERMA; FIBROBLAST; FLUORESCENT ANTIBODY TECHNIQUE; LIMITED SCLERODERMA; METABOLISM; PATHOLOGY; PATHOPHYSIOLOGY; PHYSIOLOGY; SKIN; VITAL CAPACITY;

ACUTE-PHASE PROTEINS; BIOLOGICAL MARKERS; C-REACTIVE PROTEIN; CARBON MONOXIDE; CELLS, CULTURED; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; FIBROBLASTS; FLUORESCENT ANTIBODY TECHNIQUE, INDIRECT; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; SCLERODERMA, DIFFUSE; SCLERODERMA, LIMITED; SERUM AMYLOID P-COMPONENT; SKIN; VITAL CAPACITY;

EID: 67449100026     PISSN: 0315162X     EISSN: None     Source Type: Journal    
DOI: 10.3899/jrheum.080343     Document Type: Article

References (45)

1. Sato S, Hayakawa I, Hasegawa M, Fujimoto M, Takehara K. Function blocking autoantibodies against matrix metalloproteinase-1 in patients with systemic sclerosis. J Invest Dermatol 2003;120:542-7.
2. Murrell DF. A radical proposal for the pathogenesis of scleroderma. J Am Acad Dermatol 1993;28:78-85.
3. Sambo P, Baroni SS, Luchetti M, et al. Oxidative stress in scleroderma: maintenance of scleroderma fibroblast phenotype by the constitutive up-regulation of reactive oxygen species generation through the NADPH oxidase complex pathway. Arthritis Rheum 2001;44:2653-64.
4. Abraham DJ, Varga J. Scleroderma: from cell and molecular mechanisms to disease models. Trends Immunol 2005;26:587-95.
5. Abraham D, Distler O. How does endothelial cell injury start? The role of endothelin in systemic sclerosis. Arthritis Res Ther 2007;9 Suppl 2:S2.
6. Ogawa F, Shimizu K, Muroi E, et al. Serum levels of 8-isoprostane, a marker of oxidative stress, are elevated in patients with systemic sclerosis. Rheumatology Oxford 2006;45:815-8.
7. Mendoza G, Alvarez AI, Pulido MM, et al. Inhibitory effects of different antioxidants on hyaluronan depolymerization. Carbohydr Res 2007;342:96-102.
8. Breviario F, d'Aniello EM, Golay J, et al. Interleukin-1-inducible genes in endothelial cells. Cloning of a new gene related to C-reactive protein and serum amyloid P component. J Biol Chem 1992;267:22190-7.
9. Lee GW, Lee TH, Vilcek J. TSG-14, a tumor necrosis factor- and IL-1-inducible protein, is a novel member of the pentaxin family of acute phase proteins. J Immunol 1993;150:1804-12.
10. Bottazzi B, Bastone A, Doni A, et al. The long pentraxin PTX3 as a link among innate immunity, inflammation, and female fertility. J Leukoc Biol 2006;79:909-12.
11. Presta M, Camozzi M, Salvatori G, Rusnati M. Role of the soluble pattern recognition receptor PTX3 in vascular biology. J Cell Mol Med 2007;11:723-38.
12. Bottazzi B, Vouret-Craviari V, Bastone A, et al. Multimer formation and ligand recognition by the long pentraxin PTX3. Similarities and differences with the short pentraxins C-reactive protein and serum amyloid P component. J Biol Chem 1997;272:32817-23.
13. Bottazzi B, Garlanda C, Salvatori G, Jeannin P, Manfredi A, Mantovani A. Pentraxins as a key component of innate immunity. Curr Opin Immunol 2006;18:10-5.
14. Nauta AJ, Bottazzi B, Mantovani A, et al. Biochemical and functional characterization of the interaction between pentraxin 3 and C1q. Eur J Immunol 2003;33:465-73.
15. Rovere P, Peri G, Fazzini F, et al. The long pentraxin PTX3 binds to apoptotic cells and regulates their clearance by antigen-presenting dendritic cells. Blood 2000;96:4300-6.
16. Kravitz MS, Shoenfeld Y. Autoimmunity to protective molecules: is it the perpetuum mobile (vicious cycle) of autoimmune rheumatic diseases? Nat Clin Pract Rheumatol 2006;2:481-90.
17. Garlanda C, Bottazzi B, Bastone A, Mantovani A. Pentraxins at the crossroads between innate immunity, inflammation, matrix deposition, and female fertility. Annu Rev Immunol 2005;23:337-66.
18. Muller B, Peri G, Doni A, et al. Circulating levels of the long pentraxin PTX3 correlate with severity of infection in critically ill patients. Crit Care Med 2001;29:1404-7.
19. Peri G, Introna M, Corradi D, et al. PTX3, a prototypical long pentraxin, is an early indicator of acute myocardial infarction in humans. Circulation 2000;102:636-41.
20. Bevelacqua V, Libra M, Mazzarino MC, et al. Long pentraxin 3: a marker of inflammation in untreated psoriatic patients. Int J Mol Med 2006;18:415-23.
21. Kato S, Ochiai M, Sakurada T, et al. Increased expression of long pentraxin PTX3 in inflammatory bowel diseases. Dig Dis Sci 2008;53:1910-6.
22. Fazzini F, Peri G, Doni A, et al. PTX3 in small-vessel vasculitides: an independent indicator of disease activity produced at sites of inflammation. Arthritis Rheum 2001;44:2841-50.
23. Luchetti MM, Piccinini G, Mantovani A, et al. Expression and production of the long pentraxin PTX3 in rheumatoid arthritis (RA). Clin Exp Immunol 2000;119:196-202.
24. Luchetti MM, Sambo P, Majlingova P, et al. Scleroderma fibroblasts constitutively express the long pentraxin PTX3. Clin Exp Rheumatol 2004;22:S66-72.
25. Preliminary criteria for the classification of systemic sclerosis (scleroderma). Subcommittee for Scleroderma Criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee. Arthritis Rheum 1980;23:581-90.
26. LeRoy EC, Black C, Fleischmajer R, et al. Scleroderma (systemic sclerosis): classification, subsets and pathogenesis. J Rheumatol 1988;15:202-5.
27. Clements PJ, Lachenbruch PA, Seibold JR, et al. Skin thickness score in systemic sclerosis: an assessment of interobserver variability in 3 independent studies. J Rheumatol 1993;20:1892-6.
28. Sato S, Ihn H, Kikuchi K, Takehara K. Antihistone antibodies in systemic sclerosis. Association with pulmonary fibrosis. Arthritis Rheum 1994;37:391-4.
29. Mehra TD, Ghosh K, Shu XZ, Prestwich GD, Clark RA. Molecular stenting with a crosslinked hyaluronan derivative inhibits collagen gel contraction. J Invest Dermatol 2006;126:2202-9.
30. Alles VV, Bottazzi B, Peri G, Golay J, Introna M, Mantovani A. Inducible expression of PTX3, a new member of the pentraxin family, in human mononuclear phagocytes. Blood 1994;84:3483-93.
31. Doni A, Peri G, Chieppa M, et al. Production of the soluble pattern recognition receptor PTX3 by myeloid, but not plasmacytoid, dendritic cells. Eur J Immunol 2003;33:2886-93.
32. He X, Han B, Liu M. Long pentraxin 3 in pulmonary infection and acute lung injury. Am J Physiol Lung Cell Mol Physiol 2007;292:L1039-49.
33. Termeer C, Benedix F, Sleeman J, et al. Oligosaccharides of hyaluronan activate dendritic cells via toll-like receptor 4. J Exp Med 2002;195:99-111.
34. Johnson GB, Brunn GJ, Platt JL. Cutting edge: an endogenous pathway to systemic inflammatory response syndrome (SIRS)-like reactions through Toll-like receptor 4. J Immunol 2004;172:20-4.
35. Marshak-Rothstein A. Toll-like receptors in systemic autoimmune disease. Nat Rev Immunol 2006;6:823-35.
36. Sondergaard K, Heickendorff L, Risteli L, et al. Increased levels of type I and III collagen and hyaluronan in scleroderma skin. Br J Dermatol 1997;136:47-53.
37. van Rossum AP, Pas HH, Fazzini F, et al. Abundance of the long pentraxin PTX3 at sites of leukocytoclastic lesions in patients with small-vessel vasculitis. Arthritis Rheum 2006;54:986-91.
38. Jiang D, Liang J, Fan J, et al. Regulation of lung injury and repair by Toll-like receptors and hyaluronan. Nat Med 2005;11:1173-9.
39. Neudecker BA, Stern R, Connolly MK. Aberrant serum hyaluronan and hyaluronidase levels in scleroderma. Br J Dermatol 2004;150:469-76.
40. Iannone F, Matucci-Cerinic M, Falappone PC, et al. Distinct expression of adhesion molecules on skin fibroblasts from patients with diffuse and limited systemic sclerosis. A pilot study. J Rheumatol 2005;32:1893-8.
41. Souza DG, Soares AC, Pinho V, et al. Increased mortality and inflammation in tumor necrosis factor-stimulated gene-14 transgenic mice after ischemia and reperfusion injury. Am J Pathol 2002;160:1755-65.
42. Rusnati M, Camozzi M, Moroni E, et al. Selective recognition of fibroblast growth factor-2 by the long pentraxin PTX3 inhibits angiogenesis. Blood 2004;104:92-9.
43. Camozzi M, Rusnati M, Bugatti A, et al. Identification of an antiangiogenic FGF2-binding site in the N terminus of the soluble pattern recognition receptor PTX3. J Biol Chem 2006;281:22605-13.
44. Xiang Y, Matsui T, Matsuo K, et al. Comprehensive investigation of disease-specific short peptides in sera from patients with systemic sclerosis: complement C3f-des-arginine, detected predominantly in systemic sclerosis sera, enhances proliferation of vascular endothelial cells. Arthritis Rheum 2007;56:2018-30.
45. Arason GJ, Geirsson AJ, Kolka R, Vikingsdottir T, Valdimarsson H. Deficiency of complement-dependent prevention of immune precipitation in systemic sclerosis. Ann Rheum Dis 2002;61:257-60.